Replimune Reports Q3 2025 Loss, Updates on RP1 Approval

Replimune Group Inc. reported a net loss of $66.3 million for the quarter ending December 31, 2024, an increase from $51.1 million the previous year, primarily due to rising research and development costs. The company's cash reserves stood at $536.5 million, expected to support operations until late 2026. Replimune received FDA acceptance for a Biologics License Application (BLA) for its treatment RP1 in combination with nivolumab for advanced melanoma, with a priority review set for July 22, 2025. The company is also progressing with the IGNYTE-3 trial to further assess RP1 and has initiated trials for its RP2 candidate targeting metastatic uveal melanoma and hepatocellular carcinoma. CEO Sushil Patel emphasized the importance of a strategic commercial launch upon approval. Replimune's continued focus on clinical trials and regulatory approvals is critical for its future revenue generation.